Bayer’s G4A Digital Health Partnerships Program Signs an Agreement with Eleven Digital Health Startups Transforming Digital Health Solutions

Bayer’s Vitrakvi (larotrectinib) Receives EMA’s Approval as the First Tumor Agonist in Europe


  • The program has two parts Growth Track, in which companies will receive €75 funding for co-creating solutions, as well as co-working space at Bayer’s Pharmaceuticals division headquarters in Berlin, Germany while Advance Track consist of project funds plus incremental milestone-based payments. Mentoring and Coaching is also part of G4ADigital program
  • The partnership will support the 11 companies to develop digital solutions improving patients’ health in the fields of CVD, oncology, ophthalmology, pulmonology, radiology, digital therapeutics and inflammation. Bayer selected the 11 startups from over 750 applicants across 65 countries following their strategic fit, development stage of the project, and the assessment of internal experts
  • G4A (formerly Grants4Apps) was launched in 2013 and is utilized for identifying new technologies, business models, and market trends, plus collaborating with start-ups and has supported 150 companies till date with 30+ direct collaborations

Click here to­ read full press release/ article | Ref: Bayer| Image: Behance